WHO. World Malaria Report. Geneva, Switzerland: World Health Organization; 2013.
Google Scholar
WHO. Global Report on Antimalarial Drug Efficacy and Drug Resistance 2000-2010. Geneva, Switzerland: World Health Organization; 2010.
Google Scholar
Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of artemether/lumefantrine (Coartem) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasit Vectors. 2010;3:1.
Article
PubMed Central
PubMed
Google Scholar
WHO. Malaria control today: current WHO recommendations. Geneva, Switzerland: World Health Organization; 2005.
Google Scholar
WHO. Antimalarial drug combination therapy. Report of a WHO Technical Consultation. Geneva, Switzerland: World Health Organization; 2001.
Google Scholar
Hong NV, Amambua-Ngwa A, Tuan NQ, Cuong DD, Giang NTH, Dung NV, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis. 2014;20:1199–202.
Article
PubMed
Google Scholar
Duffy PE, Sibley CH. Are we losing artemisinin combination therapy already? Lancet. 2005;366:1908–9.
Article
PubMed
Google Scholar
WHO. Guidelines for the treatment of malaria, Second edition. Geneva, Switzerland: World Health Organization; 2010.
Google Scholar
Hombhanje FW, Linge D, Saweri A, Kuanch C, Jones R, Toraso S, et al. Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar J. 2009;8:196.
Article
PubMed Central
PubMed
Google Scholar
WHO. Guidelines for the treatment of malaria. Geneva, Switzerland: World Health Organization; 2006.
Google Scholar
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, et al. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007;6:72.
Article
PubMed Central
PubMed
Google Scholar
Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, et al. Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi. Trop Med Int Health. 2004;9:673–9.
Article
PubMed
Google Scholar
Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77(6 Suppl):193–7.
PubMed
Google Scholar
Hastings IM, Watkins WM. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol. 2006;22:71–7.
Article
CAS
PubMed
Google Scholar
Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, et al. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J. 2007;6:120.
Article
PubMed Central
PubMed
Google Scholar
Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6:121.
Article
PubMed Central
PubMed
Google Scholar
Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, et al. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J. 2007;6:119.
Article
PubMed Central
PubMed
Google Scholar
Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, et al. World antimalarial resistance network (WARN) IV: Clinical pharmacology. Malar J. 2007;6:122.
Article
PubMed Central
PubMed
Google Scholar
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, et al. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J. 2010;9:53.
Article
PubMed Central
PubMed
Google Scholar
Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570–9.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
Article
PubMed
Google Scholar
WHO. Global plan for artemisinin resistance containment (GPARC). Geneva, Switzerland: World Health Organization; 2011.
Google Scholar
MHSW. National Guidelines for malaria diagnosis and treatment. Ministry of Health: United Republic of Tanzania; 2006.
Google Scholar
MoH. National Guidelines for malaria diagnosis and treatment. United Republic of Tanzania: Ministry of Health; 2000.
Google Scholar
Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, et al. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg. 2004;71:696–702.
CAS
PubMed
Google Scholar
EANMAT. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003;8:860–7.
Article
Google Scholar
EANMAT. Monitoring antimalarial drug resistance within National Malaria Control Programmes: The EANMAT experience. Trop Med Int Health. 2001;6:891–8.
Article
Google Scholar
Kitua AY. Antimalarial drug policy: making systematic change. Lancet. 1999;354:siv32.
Article
PubMed
Google Scholar
Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41:1079–86.
Article
PubMed
Google Scholar
Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis. 2011;204:1980–8.
Article
PubMed Central
CAS
PubMed
Google Scholar
Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science. 2004;305:1124.
Article
CAS
PubMed
Google Scholar
WHO. Methods for surveillance of antimalaria drug efficacy. Geneva, Switzerland: World Health Organization; 2009.
Google Scholar
Joseph D, Kabanywanyi AM, Hulser R, Premji Z, Minzi OM, Mugittu K. Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora region. Tanzania Malar J. 2013;12:60.
Article
CAS
Google Scholar
Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, et al. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malar J. 2012;11:58.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011;52:873–82.
Article
CAS
PubMed
Google Scholar
Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J. 2011;10:64.
Article
PubMed Central
PubMed
Google Scholar
Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Malar J. 2014;13:376.
Article
PubMed Central
PubMed
Google Scholar
Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146.
Article
PubMed Central
PubMed
Google Scholar
Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474–80.
Article
CAS
PubMed
Google Scholar
Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis. 2009;49:1195–201.
Article
CAS
PubMed
Google Scholar
Talisuna AO, Karema C, Ogutu B, Juma E, Logedi J, Nyandigisi A, et al. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis. 2012;12:888–96.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1:e7.
Article
PubMed Central
PubMed
Google Scholar
Juma EA, Obonyo CO, Akhwale WS, Ogutu BR. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar J. 2008;7:190.
Article
Google Scholar
Guthmann J-P, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, et al. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg. 2006;75:143–5.
CAS
PubMed
Google Scholar
Falade C, Ogundele A, Yusuf B, Ademowo O, Ladipo S. High efficacy of two artemisinin-based combinations (artemether–lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health. 2008;13:635–43.
Article
CAS
PubMed
Google Scholar
Lemnge M, Alifrangis M, Kafuye MY, Gesase S, Minja D, Massaga JJ, et al. High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, Northeastern Tanzania. Am J Trop Med Hyg. 2006;75:188–93.
CAS
PubMed
Google Scholar
Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203.
Article
PubMed Central
PubMed
Google Scholar
Thwing J, Odero C, Odhiambo F, Otieno K, Kariuki S, Ord R, et al. In vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health. 2009;14:294–300.
Article
CAS
PubMed
Google Scholar
Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Overmeir CV, et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health. 2004;9:1091–8.
Article
CAS
PubMed
Google Scholar
Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. Ombination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. Jama. 2007;297:2210–9.
Article
CAS
PubMed
Google Scholar
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45:1453–61.
Article
CAS
PubMed
Google Scholar
Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malar J. 2013;12:251.
Article
PubMed Central
CAS
PubMed
Google Scholar
Whitty CJ, Staedke SG. Artemisinin-based combination treatment for malaria in Africa: no perfect solutions. Clin Infect Dis. 2005;41:1087–8.
Article
CAS
PubMed
Google Scholar
Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, Angola. Antimicrob Agents Chemother. 2015;59:437–43.
Article
CAS
PubMed
Google Scholar
WHO. World malaria report 2008. Geneva: World Health Organization; 2008.
Google Scholar
Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis. 2010;51:571–4.
Article
PubMed
Google Scholar
van Eijk AM, Terlouw DJ. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev. 2011;2, CD006688.
PubMed
Google Scholar
Parasite Clearance Estimator (PCE) [https://www.wwarn.org/pce/].
Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.
Article
PubMed Central
PubMed
Google Scholar
Price RN, Nosten F, Luxemburger C, Ter Kuile F, Paiphun L, Price R, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347:1654–8.
Article
CAS
PubMed
Google Scholar
Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig H, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J. 2008;7:237.
Article
PubMed Central
PubMed
Google Scholar
Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9–17.
Article
CAS
PubMed
Google Scholar
Omari AA, Gamble C, Garner P. Artemether lumefantrine for uncomplicated malaria: a systematic review. Trop Med Int Health. 2004;9:192–9.
Article
CAS
PubMed
Google Scholar
White N. Preventing antimalarial drug resistance through combinations. Drug Resist Updat. 1998;1:3–9.
Article
CAS
PubMed
Google Scholar
Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8:204.
Article
PubMed Central
PubMed
Google Scholar
Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5:59.
Article
PubMed Central
PubMed
Google Scholar
Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005;365:1467–73.
Article
CAS
PubMed
Google Scholar
Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86 N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014–7.
Article
CAS
PubMed
Google Scholar
Faye B, Offianan AT, Ndiaye JL, Tine RC, Touré W, Djoman K, et al. Efficacy and tolerability of artesunate amodiaquine (Camoquin plus®) versus artemether lumefantrine (Coartem®) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health. 2010;15:608–13.
CAS
PubMed
Google Scholar
Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County. Liberia Malar J. 2013;12:250.
Article
CAS
Google Scholar
O'Dempsey T, McArdle T, Laurence B, Lamont A, Todd J, Greenwood B. Overlap in the clinical features of pneumonia and malaria in African children. Trans R Soc Trop Med Hyg. 1993;87:662–5.
Article
PubMed
Google Scholar
Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J. 2013;12:385.
Article
PubMed Central
PubMed
Google Scholar
Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and Falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan Children. PLoS One. 2014;9:e105690.
Article
PubMed Central
PubMed
Google Scholar
Ghansah A, Amenga-Etego L, Amambua-Ngwa A, Andagalu B, Apinjoh T, Bouyou-Akotet M, et al. Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. Science. 2014;345:1297–8.
Article
CAS
PubMed
Google Scholar